se of low dose of Dexmedetomidine in Neurosurgical Patients for better outcomes
Phase 4
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecifiedHealth Condition 2: C719- Malignant neoplasm of brain, unspecifiedHealth Condition 3: C700- Malignant neoplasm of cerebral meninges
- Registration Number
- CTRI/2023/10/058666
- Lead Sponsor
- Rajendra institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patient giving informed and written consent
2.ASA physical class 1 and 2
3.Patient of supratentorial space occupying lesion
4.Glasgow coma scale 15/15
Exclusion Criteria
1.Patient refusal, not giving consent for study.
2.Pregnant and lactating women.
3.Patients undergoing elective surgical procedures in prone position including surgery of spine.
4.Patient having known case of allergy to dexmedetomidine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To observe the hemodynamic changes during tracheal extubation following two infusion doses of dexmedetomidine. <br/ ><br>To observe the airway response during tracheal extubationTimepoint: 30 minutes after completion of surgery
- Secondary Outcome Measures
Name Time Method 1. Time to emergence & time to tracheal extubation. <br/ ><br>2.Early post operative complications such as coughing, laryngospasm, <br/ ><br>bronchospasm. <br/ ><br>3.Adverse effects of the drug if any, such as delayed arousal, bradycardia & hypotension.Timepoint: 1 hour after tracheal extubation